- Earth Science Tech has launched a new sales division focused on CBD, led by Industry-veteran Erika Franck
- ETST’s portfolio is positioned in the dually lucrative biotechnology and cannabis/cannabidiol industries
- Biotechnology currently represents the largest segment of the growing legal cannabis market
Earth Science Tech Inc. (OTCQB: ETST) recently launched a new sales unit to further strengthen its position in the CBD marketplace for medical and pharmaceutical products. Erika Franck, who has previously served as the company’s clinical and therapeutics sales director, will be heading the division. ETST made this move in accordance with the growing use of CBD in the licensed medical fields and alternate medicinal streams.
The company, under the leadership of Franck, will target medical experts and specialists, suppliers, acupuncturists, chiropractors, practitioners of holistic wellness and alternative therapies, and veterinarians. With the appointment of Franck, the company receives her sound knowledge and experience in the pharmaceutical and orthopedics industry.
“I am thrilled to be part of this amazing team and to have the opportunity to apply my expertise in spearheading this new clinical division for ETST,” Franck stated in a news release (http://cnw.fm/DoS5h). “Our shared vision is to improve patients’ quality of life, and I am honored to participate in ETST’s continued growth as we achieve this mission.”
Earth Science Tech is well-positioned as a biotechnology company which focuses on the research and development of CBD, pharmaceuticals and medical device products. The company’s pure CBD oil is manufactured using CO2 liquid extraction processes; ETST prides itself on offering the finest quality pure CBD oil on the market.
The biotechnology segment of the cannabis industry consists of pharmaceutical firms focused on the research and development behind new drugs and products that utilize cannabinoids, which are the active compounds within cannabis. Currently the largest sector in the legal cannabis market, it is expected to see further growth as more entities around the world continue researching cannabinoids (http://cnw.fm/b5sGr). This trend is encouraging for biotechnology companies like Florida-based ETST.
ETST projects a robust portfolio through its two wholly owned subsidiaries, which are focused on the research and production of cutting-edge industrial hemp and cannabis/cannabidiol (CBD) products to take advantage of the potential seen in the burgeoining cannabis industry.
ETST subsidiary Earth Science Pharma Inc. is engaged in the production of noninvasive economical diagnostic testing tools, medical devices and vaccines for sexually transmitted infections and/or diseases. Their first STI home detection kit using a modified panty liner (MSN-2), named Hygee, is a revolutionary product that can be used for chlamydia testing by women from their homes. The MSN-2 technology is further being utilized to screen for other STIs such as gonorrhea and thichomoniasis, and it holds disruptive potential in the women’s health sector.
Cannabis Therapeutics Inc., another of ETST’s subsidiaries, was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis/cannabinoid-based pharmaceuticals, nutraceuticals and other products and solutions.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://cnw.fm/ETST
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor